An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Nigel Bark MD, Bronx Psychiatric Center
ClinicalTrials.gov Identifier:
NCT00823199
First received: January 14, 2009
Last updated: March 21, 2013
Last verified: March 2013

January 14, 2009
March 21, 2013
November 2005
August 2008   (final data collection date for primary outcome measure)
Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia [ Time Frame: baseline to 4 weeks ] [ Designated as safety issue: No ]
Symptom scale Score 30 (best) to 210 (worst)
Change in PANSS [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00823199 on ClinicalTrials.gov Archive Site
Simpson Angus Scale for Parkinsonism [ Time Frame: baseline to 4 weeks ] [ Designated as safety issue: Yes ]
Measures drug induced parkinsonism, score 0 (best) to 36 (worst)
Movement disorder ratings [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia
An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia

This is a four week open label trial of ALLOPURINOL to the treatment regime of ten (10) poorly responsive patients with schizophrenia, monitoring their response and side-effects. No change in medication is required.

Not Provided
Interventional
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Schizophrenia
Drug: Allopurinal
300mg once daily by mouth for four weeks
Experimental: Allopurianal treatment
Allopurinal 300mg once daily by mouth for four weeks
Intervention: Drug: Allopurinal
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
August 2008
August 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects with schizophrenia and poor response (no prospect of discharge because of symptoms)

Exclusion Criteria:

  • Over 65
  • Renal or liver disease
  • Diabetes
  • Hypertension
  • Taking thiazides or ACE inhibitors
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00823199
ICFV12/02
No
Nigel Bark MD, Bronx Psychiatric Center
Bronx Psychiatric Center
Not Provided
Principal Investigator: Nigel Bark, MD Bronx Psychiatric Center
Bronx Psychiatric Center
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP